AT500379B8 - Tau-proteine - Google Patents

Tau-proteine Download PDF

Info

Publication number
AT500379B8
AT500379B8 AT0017501A AT1752001A AT500379B8 AT 500379 B8 AT500379 B8 AT 500379B8 AT 0017501 A AT0017501 A AT 0017501A AT 1752001 A AT1752001 A AT 1752001A AT 500379 B8 AT500379 B8 AT 500379B8
Authority
AT
Austria
Prior art keywords
tau
tau proteins
normal
proteins
conformationally different
Prior art date
Application number
AT0017501A
Other languages
English (en)
Other versions
AT500379B1 (de
AT500379A3 (de
AT500379A2 (de
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0017501A priority Critical patent/AT500379B8/de
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Priority to CA2437453A priority patent/CA2437453C/en
Priority to AU2002237296A priority patent/AU2002237296A1/en
Priority to CNA2008101081547A priority patent/CN101307107A/zh
Priority to ES02703586T priority patent/ES2339427T3/es
Priority to PCT/EP2002/000897 priority patent/WO2002062851A1/en
Priority to DK02703586.4T priority patent/DK1355949T3/da
Priority to EP02703586A priority patent/EP1355949B1/de
Priority to AT02703586T priority patent/ATE461941T1/de
Priority to US10/470,928 priority patent/US7446180B2/en
Priority to DE60235746T priority patent/DE60235746D1/de
Priority to JP2002563203A priority patent/JP4163955B2/ja
Priority to CNB028053133A priority patent/CN100503638C/zh
Priority to RU2003126594/13A priority patent/RU2299889C2/ru
Publication of AT500379A2 publication Critical patent/AT500379A2/de
Priority to US12/264,694 priority patent/US20090123936A1/en
Publication of AT500379A3 publication Critical patent/AT500379A3/de
Application granted granted Critical
Publication of AT500379B1 publication Critical patent/AT500379B1/de
Publication of AT500379B8 publication Critical patent/AT500379B8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0017501A 2001-02-02 2001-02-02 Tau-proteine AT500379B8 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
DE60235746T DE60235746D1 (de) 2001-02-02 2002-01-29 Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
CNA2008101081547A CN101307107A (zh) 2001-02-02 2002-01-29 tau蛋白
ES02703586T ES2339427T3 (es) 2001-02-02 2002-01-29 Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer.
PCT/EP2002/000897 WO2002062851A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
DK02703586.4T DK1355949T3 (da) 2001-02-02 2002-01-29 Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom
EP02703586A EP1355949B1 (de) 2001-02-02 2002-01-29 Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
CA2437453A CA2437453C (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
AU2002237296A AU2002237296A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
JP2002563203A JP4163955B2 (ja) 2001-02-02 2002-01-29 構造的に異常な形のタウタンパク質およびそれに対する特異抗体
CNB028053133A CN100503638C (zh) 2001-02-02 2002-01-29 tau蛋白
RU2003126594/13A RU2299889C2 (ru) 2001-02-02 2002-01-29 Конформационно аномальные формы белков тау и специфические антитела к ним
US10/470,928 US7446180B2 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
US12/264,694 US20090123936A1 (en) 2001-02-02 2008-11-04 Conformationally abnormal forms of tau proteins and specific antibodies thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine

Publications (4)

Publication Number Publication Date
AT500379A2 AT500379A2 (de) 2005-12-15
AT500379A3 AT500379A3 (de) 2009-02-15
AT500379B1 AT500379B1 (de) 2009-07-15
AT500379B8 true AT500379B8 (de) 2009-08-15

Family

ID=3658236

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Country Status (12)

Country Link
US (2) US7446180B2 (de)
EP (1) EP1355949B1 (de)
JP (1) JP4163955B2 (de)
CN (2) CN100503638C (de)
AT (2) AT500379B8 (de)
AU (1) AU2002237296A1 (de)
CA (1) CA2437453C (de)
DE (1) DE60235746D1 (de)
DK (1) DK1355949T3 (de)
ES (1) ES2339427T3 (de)
RU (1) RU2299889C2 (de)
WO (1) WO2002062851A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AU2003253044B2 (en) * 2002-07-12 2009-08-13 Axon Neuroscience Se Truncated tau proteins
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
WO2010144711A2 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2772379C (en) * 2009-08-28 2019-09-24 Rakez Kayed Antibodies that bind tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
ITRM20100320A1 (it) * 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
US9506051B2 (en) * 2011-05-20 2016-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
SG10201912964PA (en) * 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US9598485B2 (en) * 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) * 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
EP3334453A4 (de) 2015-08-13 2019-02-06 New York University Antikörperbasierte, für das verkürzte asp421-epitop von tau spezifische moleküle und deren verwendungen in der diagnose und behandlung von tauopathie
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
NZ748983A (en) * 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN107686839B (zh) * 2017-09-25 2020-12-04 安徽朵能生物科技有限公司 微管结合蛋白cript、其治疗性突变体及其应用
EP3829634A1 (de) 2018-07-31 2021-06-09 Eli Lilly and Company Kombinationstherapie
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
WO2020190932A1 (en) 2019-03-18 2020-09-24 Regeneron Pharmaceuticals, Inc. Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
EP4271708A1 (de) 2020-12-29 2023-11-08 Neurimmune AG Menschliche anti-tau-antikörper

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation

Also Published As

Publication number Publication date
EP1355949A1 (de) 2003-10-29
DK1355949T3 (da) 2010-05-25
AU2002237296A1 (en) 2002-08-19
EP1355949B1 (de) 2010-03-24
WO2002062851A8 (en) 2002-09-12
CA2437453C (en) 2013-06-11
JP2004532817A (ja) 2004-10-28
RU2003126594A (ru) 2005-03-10
CN100503638C (zh) 2009-06-24
AT500379B1 (de) 2009-07-15
CN1492879A (zh) 2004-04-28
US7446180B2 (en) 2008-11-04
WO2002062851A1 (en) 2002-08-15
RU2299889C2 (ru) 2007-05-27
AT500379A3 (de) 2009-02-15
DE60235746D1 (de) 2010-05-06
US20090123936A1 (en) 2009-05-14
ES2339427T3 (es) 2010-05-20
JP4163955B2 (ja) 2008-10-08
AT500379A2 (de) 2005-12-15
ATE461941T1 (de) 2010-04-15
US20040082763A1 (en) 2004-04-29
CN101307107A (zh) 2008-11-19
CA2437453A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
AT500379B1 (de) Tau-proteine
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP3569610A3 (de) Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EP2147928A3 (de) Auf Peptiden basierte Immunisierungstherapie zur Behandlung von Atherosklerose und Entwicklung von Peptid-basierten Assays zur Bestimmung von Immunreaktionen gegen oxidiertes Lipoprotein geringer Dichte
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP2267032A3 (de) Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
EP2305286A3 (de) Behandlung von Alzheimerkrankheit
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
DE602004011770D1 (de) Fusionsproteine
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
WO2000078344A8 (en) Prion protein peptides and uses thereof
EP1541686A4 (de) Antikörperkonstruktion unter verwendung einer mrl/lpr-maus
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
EA200400134A1 (ru) Терапевтический агент
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2002046769A3 (en) A monoclonal antibody-based diagnostic assay for gamma fibrinogen
WO2006131562A3 (en) Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: AXON NEUROSCIENCE SE, CY

Effective date: 20191118

MK07 Expiry

Effective date: 20210202